Core Laboratories Analyst Ratings
Core Laboratories Analyst Ratings
核心實驗室分析師評級
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/18/2023 | -19.45% | Citigroup | $21 → $20 | Maintains | Sell |
| 07/31/2023 | -15.42% | Piper Sandler | $19 → $21 | Maintains | Neutral |
| 06/30/2023 | -15.42% | Citigroup | $22 → $21 | Downgrades | Neutral → Sell |
| 05/01/2023 | -23.48% | Piper Sandler | $18 → $19 | Maintains | Neutral |
| 04/28/2023 | 0.68% | Stifel | $24 → $25 | Maintains | Hold |
| 04/18/2023 | -13.41% | B of A Securities | → $21.5 | Downgrades | Neutral → Underperform |
| 02/07/2023 | 4.71% | Citigroup | $21 → $26 | Maintains | Neutral |
| 01/09/2023 | — | B of A Securities | Upgrades | Underperform → Neutral | |
| 10/07/2022 | — | Citigroup | Upgrades | Sell → Neutral | |
| 09/26/2022 | -19.45% | Morgan Stanley | → $20 | Downgrades | Equal-Weight → Underweight |
| 08/01/2022 | -19.45% | Morgan Stanley | $22 → $20 | Maintains | Equal-Weight |
| 07/13/2022 | -11.4% | Morgan Stanley | $32 → $22 | Maintains | Equal-Weight |
| 05/02/2022 | 28.88% | Morgan Stanley | $35 → $32 | Maintains | Equal-Weight |
| 04/18/2022 | -14.22% | Piper Sandler | $19.5 → $21.3 | Downgrades | Neutral → Underweight |
| 04/11/2022 | 40.96% | Morgan Stanley | $30 → $35 | Maintains | Equal-Weight |
| 01/18/2022 | 20.82% | Morgan Stanley | $32 → $30 | Maintains | Equal-Weight |
| 12/07/2021 | 28.88% | Morgan Stanley | $34 → $32 | Maintains | Equal-Weight |
| 10/18/2021 | 28.88% | B of A Securities | $36 → $32 | Downgrades | Neutral → Underperform |
| 10/11/2021 | 36.93% | Morgan Stanley | $37 → $34 | Maintains | Equal-Weight |
| 08/03/2021 | 49.01% | Morgan Stanley | $40 → $37 | Maintains | Equal-Weight |
| 07/09/2021 | 61.1% | Morgan Stanley | → $40 | Downgrades | Overweight → Equal-Weight |
| 06/14/2021 | 44.99% | Citigroup | $30 → $36 | Downgrades | Neutral → Sell |
| 03/25/2021 | 53.04% | Morgan Stanley | $33 → $38 | Maintains | Overweight |
| 12/18/2020 | -27.51% | JP Morgan | → $18 | Downgrades | Neutral → Underweight |
| 11/10/2020 | — | Morgan Stanley | Upgrades | Equal-Weight → Overweight | |
| 10/26/2020 | 0.68% | Morgan Stanley | $24 → $25 | Maintains | Equal-Weight |
| 09/29/2020 | — | ABN Amro | Upgrades | Sell → Hold | |
| 07/27/2020 | -35.56% | Piper Sandler | $15 → $16 | Maintains | Neutral |
| 07/24/2020 | -11.4% | Stifel | $15 → $22 | Maintains | Hold |
| 07/16/2020 | -23.48% | Scotiabank | → $19 | Downgrades | Sector Outperform → Sector Perform |
| 07/08/2020 | -3.34% | Morgan Stanley | $18 → $24 | Maintains | Equal-Weight |
| 05/19/2020 | -27.51% | Morgan Stanley | $12 → $18 | Maintains | Equal-Weight |
| 04/24/2020 | -39.59% | Stifel | $14 → $15 | Maintains | Hold |
| 04/13/2020 | -47.64% | Scotiabank | $40 → $13 | Upgrades | Sector Perform → Sector Outperform |
| 04/07/2020 | -69.79% | Piper Sandler | $16.5 → $7.5 | Maintains | Neutral |
| 03/18/2020 | -43.62% | Stifel | $17 → $14 | Maintains | Hold |
| 03/17/2020 | -35.56% | JP Morgan | $39 → $16 | Maintains | Neutral |
| 03/16/2020 | -51.67% | Morgan Stanley | $45 → $12 | Maintains | Equal-Weight |
| 03/13/2020 | -55.7% | Citigroup | $40 → $11 | Maintains | Neutral |
| 03/10/2020 | -31.53% | Stifel | $40 → $17 | Maintains | Hold |
| 03/09/2020 | — | B of A Securities | Downgrades | Buy → Underperform | |
| 01/30/2020 | — | Johnson Rice | Reinstates | → Buy | |
| 01/14/2020 | 56.26% | Bernstein | → $38.8 | Initiates Coverage On | → Market Perform |
| 01/02/2020 | 61.1% | Stifel | $50 → $40 | Downgrades | Buy → Hold |
| 12/31/2019 | 57.07% | Cowen & Co. | $42 → $39 | Maintains | Market Perform |
| 12/10/2019 | 85.26% | Citigroup | $44 → $46 | Maintains | Neutral |
| 10/18/2019 | 77.2% | Citigroup | $51 → $44 | Maintains | Neutral |
| 10/07/2019 | 121.51% | Morgan Stanley | $65 → $55 | Maintains | Equal-Weight |
| 09/11/2019 | 105.4% | Citigroup | $54 → $51 | Maintains | Neutral |
| 07/12/2019 | 181.92% | Morgan Stanley | $75 → $70 | Maintains | Equal-Weight |
| 07/10/2019 | 153.73% | B of A Securities | → $63 | Upgrades | Neutral → Buy |
| 01/04/2019 | 165.81% | Citigroup | $76 → $66 | Maintains | Neutral |
| 12/19/2018 | 202.05% | Credit Suisse | $105 → $75 | Downgrades | Outperform → Neutral |
| 12/12/2018 | 218.16% | JP Morgan | $111 → $79 | Maintains | Neutral |
| 12/11/2018 | 218.16% | JP Morgan | $111 → $79 | Downgrades | Overweight → Neutral |
| 11/16/2018 | — | Guggenheim | Upgrades | Neutral → Buy | |
| 11/01/2018 | — | ABN Amro | Upgrades | Sell → Buy | |
| 10/29/2018 | 322.88% | Morgan Stanley | $115 → $105 | Maintains | Equal-Weight |
| 10/29/2018 | 343.01% | Stifel | $117 → $110 | Upgrades | Hold → Buy |
| 10/26/2018 | 322.88% | Credit Suisse | $122 → $105 | Maintains | Outperform |
| 10/11/2018 | 363.15% | Morgan Stanley | $125 → $115 | Maintains | Equal-Weight |
| 09/19/2018 | 403.42% | Morgan Stanley | → $125 | Initiates Coverage On | → Equal-Weight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/18/2023 | -19.45% | 花旗集團 | $21→$20 | 維護 | 賣 |
| 07/31/2023 | -15.42% | 派珀·桑德勒 | $19→$21 | 維護 | 中性 |
| 2023/06/30 | -15.42% | 花旗集團 | $22→$21 | 評級下調 | 中性→銷售 |
| 05/01/2023 | -23.48% | 派珀·桑德勒 | $18→$19 | 維護 | 中性 |
| 04/28/2023 | 0.68% | Stifel | $24→$25 | 維護 | 保持 |
| 04/18/2023 | -13.41% | B of A證券 | →$21.5 | 評級下調 | 中性→表現不佳 |
| 02/07/2023 | 4.71% | 花旗集團 | $21→$26 | 維護 | 中性 |
| 01/09/2023 | - | B of A證券 | 升級 | 表現不佳的→中性 | |
| 10/07/2022 | - | 花旗集團 | 升級 | 賣出→中性 | |
| 09/26/2022 | -19.45% | 摩根士丹利 | →$20 | 評級下調 | 等重→減碼 |
| 08/01/2022 | -19.45% | 摩根士丹利 | $22→$20 | 維護 | 等重 |
| 07/13/2022 | -11.4% | 摩根士丹利 | $32→$22 | 維護 | 等重 |
| 05/02/2022 | 28.88% | 摩根士丹利 | $35→$32 | 維護 | 等重 |
| 04/18/2022 | -14.22% | 派珀·桑德勒 | $19.5→$21.3 | 評級下調 | 中性→減持 |
| 04/11/2022 | 40.96% | 摩根士丹利 | $30→$35 | 維護 | 等重 |
| 01/18/2022 | 20.82% | 摩根士丹利 | $32→$30 | 維護 | 等重 |
| 12/07/2021 | 28.88% | 摩根士丹利 | $34→$32 | 維護 | 等重 |
| 10/18/2021 | 28.88% | B of A證券 | $36→$32 | 評級下調 | 中性→表現不佳 |
| 10/11/2021 | 36.93% | 摩根士丹利 | $37→$34 | 維護 | 等重 |
| 08/03/2021 | 49.01% | 摩根士丹利 | $40→$37 | 維護 | 等重 |
| 07/09/2021 | 61.1% | 摩根士丹利 | →$40 | 評級下調 | 超重→等重 |
| 2021/06/14 | 44.99% | 花旗集團 | $30→$36 | 評級下調 | 中性→銷售 |
| 03/25/2021 | 53.04% | 摩根士丹利 | $33→$38 | 維護 | 超重 |
| 12/18/2020 | -27.51% | 摩根大通 | →$18 | 評級下調 | 中性→減持 |
| 11/10/2020 | - | 摩根士丹利 | 升級 | 等重→超重 | |
| 10/26/2020 | 0.68% | 摩根士丹利 | $24→$25 | 維護 | 等重 |
| 09/29/2020 | - | 荷蘭銀行 | 升級 | 銷售→Hold | |
| 07/27/2020 | -35.56% | 派珀·桑德勒 | $15→$16 | 維護 | 中性 |
| 07/24/2020 | -11.4% | Stifel | $15→$22 | 維護 | 保持 |
| 07/16/2020 | -23.48% | 加拿大豐業銀行 | →$19 | 評級下調 | 行業表現優於→行業表現 |
| 07/08/2020 | -3.34% | 摩根士丹利 | $18→$24 | 維護 | 等重 |
| 2020/05/19 | -27.51% | 摩根士丹利 | $12→$18 | 維護 | 等重 |
| 04/24/2020 | -39.59% | Stifel | $14→$15 | 維護 | 保持 |
| 04/13/2020 | -47.64% | 加拿大豐業銀行 | $40→$13 | 升級 | 行業表現優於→行業表現 |
| 04/07/2020 | -69.79% | 派珀·桑德勒 | $16.5→$7.5 | 維護 | 中性 |
| 03/18/2020 | -43.62% | Stifel | $17→$14 | 維護 | 保持 |
| 03/17/2020 | -35.56% | 摩根大通 | $39→$16 | 維護 | 中性 |
| 03/16/2020 | -51.67% | 摩根士丹利 | $45→$12 | 維護 | 等重 |
| 03/13/2020 | -55.7% | 花旗集團 | $40→$11 | 維護 | 中性 |
| 03/10/2020 | -31.53% | Stifel | $40→$17 | 維護 | 保持 |
| 03/09/2020 | - | B of A證券 | 評級下調 | 購買表現不佳的→ | |
| 1/30/2020 | - | 約翰遜大米 | 恢復 | →購買 | |
| 2020/01/14 | 56.26% | 伯恩斯坦 | →$38.8 | 開始承保 | →市場表現 |
| 1/02/2020 | 61.1% | Stifel | $50→$40 | 評級下調 | 購買→Hold |
| 2019年12月31日 | 57.07% | 考恩公司 | $42→$39 | 維護 | 市場表現 |
| 2019年12月10日 | 85.26% | 花旗集團 | $44→$46 | 維護 | 中性 |
| 2019年10月18日 | 77.2% | 花旗集團 | $51→$44 | 維護 | 中性 |
| 2019/07/10 | 121.51% | 摩根士丹利 | $65→$55 | 維護 | 等重 |
| 2019/11/09 | 105.4% | 花旗集團 | $54→$51 | 維護 | 中性 |
| 2019年07月12日 | 181.92% | 摩根士丹利 | $75→$70 | 維護 | 等重 |
| 2019年07月10日 | 153.73% | B of A證券 | →$63 | 升級 | 中性→購買 |
| 2019年04月01日 | 165.81% | 花旗集團 | $76→$66 | 維護 | 中性 |
| 2018年12月19日 | 202.05% | 瑞士信貸 | $105→$75 | 評級下調 | 跑贏→中性 |
| 2018年12月12日 | 218.16% | 摩根大通 | $111→$79 | 維護 | 中性 |
| 2018年12月11日 | 218.16% | 摩根大通 | $111→$79 | 評級下調 | 超重→中性 |
| 2018年11月16日 | - | 古根海姆 | 升級 | 中性→購買 | |
| 2018/11/01 | - | 荷蘭銀行 | 升級 | 賣出→買入 | |
| 2018年10月29日 | 322.88% | 摩根士丹利 | $115→$105 | 維護 | 等重 |
| 2018年10月29日 | 343.01% | Stifel | $117→$110 | 升級 | 持有→購買 |
| 2018年10月26日 | 322.88% | 瑞士信貸 | $122→$105 | 維護 | 跑贏大盤 |
| 2018年10月11日 | 363.15% | 摩根士丹利 | $125→$115 | 維護 | 等重 |
| 2018年09月19日 | 403.42% | 摩根士丹利 | →$125 | 開始承保 | →等重 |
What is the target price for Core Laboratories (CLB)?
核心實驗室(CLB)的目標價格是多少？
The latest price target for Core Laboratories (NYSE: CLB) was reported by Citigroup on September 18, 2023. The analyst firm set a price target for $20.00 expecting CLB to fall to within 12 months (a possible -19.45% downside). 10 analyst firms have reported ratings in the last year.
核心實驗室(紐約證券交易所代碼：CLB)的最新目標價是由花旗集團於2023年9月18日報告的。這家分析公司將目標價定為20.00美元，預計CLB將在12個月內下跌(可能下跌19.45%)。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Core Laboratories (CLB)?
核心實驗室(CLB)的最新分析師評級是多少？
The latest analyst rating for Core Laboratories (NYSE: CLB) was provided by Citigroup, and Core Laboratories maintained their sell rating.
核心實驗室(紐約證券交易所代碼：CLB)的最新分析師評級由花旗集團提供，核心實驗室維持其賣出評級。
When is the next analyst rating going to be posted or updated for Core Laboratories (CLB)?
核心實驗室(CLB)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Core Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Core Laboratories was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.
分析師在進行了廣泛的研究後得出了股票評級，這些研究包括查閱公共財務報表，與核心實驗室的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。核心實驗室的上一次評級是在2023年9月18日提交的，所以你應該預計下一次評級將在2024年9月18日左右的某個時候公佈。
Is the Analyst Rating Core Laboratories (CLB) correct?
分析師對核心實驗室(CLB)的評級正確嗎？
While ratings are subjective and will change, the latest Core Laboratories (CLB) rating was a maintained with a price target of $21.00 to $20.00. The current price Core Laboratories (CLB) is trading at is $24.83, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的核心實驗室(CLB)評級維持不變，目標價在21.00美元至20.00美元之間。核心實驗室(CLB)目前的交易價格為24.83美元，超出了分析師的預測範圍。